文献速递白血病造血干细胞移植与细胞治疗

母细胞性浆细胞样树突细胞肿瘤:398例成人患者国际调查结果

Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.
PubMed 文献 · Blood Adv · 2020-01-01

该国际调查纳入75个中心的398例成人BPDCN患者,评估不同治疗方案的预后。中位随访12个月,中位OS为18个月;接受淋巴瘤样或急性白血病样方案化疗后桥接异基因造血干细胞移植者预后最佳,中位OS未达到(P < .001)。

要点

  • 化疗后桥接移植是BPDCN预后最佳的治疗策略。
  • 异基因造血干细胞移植巩固可能优于自体移植。
  • 未接受巩固治疗或仅姑息治疗者生存期明显较短。

核心结论

  • 在BPDCN中,采用淋巴瘤样或急性白血病样方案化疗后桥接移植,是与最佳结局相关的治疗策略。
  • 在可行的情况下,异基因造血干细胞移植巩固似乎优于自体造血干细胞移植。

研究设计与样本

  • 国际多中心回顾性调查,纳入来自75个中心的398例成人BPDCN患者。

主要发现

  • 中位随访12个月,中位总生存期(OS)为18个月。
  • 接受淋巴瘤样或急性白血病样方案化疗后桥接异基因HSCT者结局最佳,中位OS未达到。
  • 接受自体HSCT者中位OS为65个月;未接受巩固治疗的急性白血病样方案和淋巴瘤样方案治疗者中位OS分别为18个月和14个月;接受姑息治疗者中位OS为4个月(P < .001)。

临床怎么用

  • 对适合的BPDCN成人患者,可考虑采用淋巴瘤样或急性白血病样方案化疗后桥接异基因造血干细胞移植。
  • 在制定移植策略时,异基因HSCT可能优先于自体HSCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study is to describe the clinical and prognostic features and to evaluate the outcome of different therapeutic approaches among patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have been diagnosed and treated in different institutions. A total of 398 patients from 75 centers were included in the study. Treatment consisted of non-Hodgkin lymphoma (NHL)-like regimens in 129 (32.8%) patients and acute leukemia (AL)-like regimens in 113 (23.5%) patients. In 61 (15.5%) and 16 (4.1%) patients, chemotherapy was followed by allogeneic and autologous hematopoietic stem cell transplantation (HSCT), respectively. Twenty-seven (6.9%) patients received radiotherapy, 6 (1.5%) received new agents, and 62 (15.7%) received palliative care. After a median follow-up of 12 months, median overall survival (OS) was 18 months. Patients who received NHL/AL-like regimens, followed by allogeneic HSCT, had the best outcome; median OS was not reached. OS was 65 months for patients who underwent autologous HSCT; 18 months and 14 months, respectively, for those treated with AL-like and NHL-like regimens without consolidation; and 4 months for those receiving palliative care (P < .001). In BPDCN, chemotherapy with lymphoma- or AL-like regimens, followed by transplantation, represents the therapeutic strategy associated with the best outcome. Consolidation with allogeneic HSCT, when feasible, appears superior to autologous HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Laribi K, Baugier de Materre A, Sobh M, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020. PMID: 33027528. doi:10.1182/bloodadvances.2020002474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。